Oxidative Stress during HIV Infection: Mechanisms and Consequences

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Ivanov, Alexander V ^a   Valuev Elliston, Vladimir T ^a   Ivanova, Olga N ^a   Kochetkov, Sergey N ^a   Starodubova, Elizaveta S ^a,b   Bartosch, Birke ^c,d   Isaguliants, Maria G ^e,f,g  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES   (Russian Federation)

^c CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^d DevWeCan Laboratories of Excellence Network (Labex)   (France)

^e RIGA STRADINS UNIVERSITY   (Latvia)

^f KAROLINSKA INSTITUTE   (Sweden)

^g GAMALEYA RESEARCH INSTITUTE OF EPIDEMIOLOGY AND MICROBIOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULES; NETWORK SECURITY; PATHOLOGY; VIRUSES;

ANTIRETROVIRALS; BIOLOGICAL MOLECULE; DEFENSE MECHANISM; HUMAN IMMUNODEFICIENCY VIRUS TYPE-1; NITROSATIVE STRESS; OXIDATIVE STRESS MARKERS; REACTIVE OXYGEN SPECIES; SIGNALING MOLECULES;

DISEASES;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIOXIDANT; CD8 ANTIGEN; REACTIVE OXYGEN METABOLITE; OXIDIZING AGENT;

ANTIVIRAL THERAPY; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; DEMENTIA; DISEASE PREDISPOSITION; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; LUNG DISEASE; LUNG INFECTION; NEUROTOXICITY; NITROSATIVE STRESS; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOGENICITY; PERITONEUM MACROPHAGE; REVIEW; TH2 CELL; ANIMAL; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HIV INFECTIONS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; OXIDATION REDUCTION REACTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VIROLOGY; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; OXIDANTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 84994056587     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/8910396     Document Type: Review

References (244)

1. M. Gutowski and S. Kowalczyk, "A study of free radical chemistry: their role and pathophysiological significance," Acta Biochimica Polonica, vol. 60, no. 1, pp. 1-16, 2013.
2. O. Augusto and S. Miyamoto, "Oxygen radicals and related species," in Principles of Free Radical Biomedicine, K. Pantopoulos and H.M. Schipper, Eds., pp. 1-23, Nova Science Publishers, 2011.
3. A. Bindoli and M. P. Rigobello, "Principles in redox signaling: from chemistry to functional significance," Antioxidants & Redox Signaling, vol. 18, no. 13, pp. 1557-1593, 2013.
4. B. Enyedi, P. Várnai, M. Geiszt, "Redox state of the endoplasmic reticulum is controlled by Ero1L-alpha and intraluminal calcium," Antioxidants & Redox Signaling, vol. 13, no. 6, pp. 721-729, 2010.
5. R. A. Casero Jr. and A. E. Pegg, "Polyamine catabolism and disease," Biochemical Journal, vol. 421, no. 3, pp. 323-338, 2009.
6. K. Bedard and K.-H. Krause, "The NOX family of ROSgeneratingNADPHoxidases: physiology and pathophysiology," Physiological Reviews, vol. 87, no. 1, pp. 245-313, 2007.
7. T. R. Figueira, M. H. Barros, A. A. Camargo et al., "Mitochondria as a source of reactive oxygen and nitrogen species: from molecular mechanisms to human health," Antioxidants and Redox Signaling, vol. 18, no. 16, pp. 2029-2074, 2013.
8. Y. Nisimoto, B. A. Diebold, D. Constentino-Gomes, J. D. Lambeth, "Nox4: a hydrogen peroxide-generating oxygen sensor," Biochemistry, vol. 53, no. 31, pp. 5111-5120, 2014.
9. S. Bhattacharyya, K. Sinha, P. C. Sil, "Cytochrome P450s: mechanisms and biological implications in drug metabolism and its interaction with oxidative stress," Current Drug Metabolism, vol. 15, no. 7, pp. 719-742, 2014.
10. A. Görlach, P. Klappa, T. Kietzmann, "The endoplasmic reticulum: folding, calcium homeostasis, signaling, redox control," Antioxidants and Redox Signaling, vol. 8, no. 9-10, pp. 1391-1418, 2006.
11. N. Cantu-Medellin and E. E. Kelley, "Xanthine oxidoreductasecatalyzed reactive species generation: a process in critical need of reevaluation," Redox Biology, vol. 1, no. 1, pp. 353-358, 2013.
12. P. Pacher, A. Nivorozhkin, C. Szabó, "Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol," Pharmacological Reviews, vol. 58, no. 1, pp. 87-114, 2006.
13. B. Halliwell and J. M. C. Gutteridge, "Oxygen toxicity, oxygen radicals, transition metals and disease," Biochemical Journal, vol. 219, no. 1, pp. 1-14, 1984.
14. A. Ayala, M. F. Muñoz, S. Arguëlles, "Lipid peroxidation: production, metabolism, signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal," Oxidative Medicine and Cellular Longevity, vol. 2014,Article ID 360438, 31 pages, 2014.
15. S. T. Mayne, "Antioxidant nutrients and chronic disease: use of biomarkers of exposure and oxidative stress status in epidemiologic research," The Journal of Nutrition, vol. 133, supplement 3, pp. 933S-940S, 2003.
16. C. C. Winterbourn, "Reconciling the chemistry and biology of reactive oxygen species," Nature Chemical Biology, vol. 4, no. 5, pp. 278-286, 2008.
17. B. D'Autreaúx and M. B. Toledano, "ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis," Nature Reviews Molecular Cell Biology, vol. 8, no. 10, pp. 813-824, 2007.
18. M.Dynowski, G. Schaaf,D. Loque,O.Moran, U. Ludewig, "Plant plasma membrane water channels conduct the signalling molecule H2O2," Biochemical Journal, vol. 414, no. 1, pp. 53-61, 2008.
19. H. J. Forman, K. J. A. Davies, F. Ursini, "Howdo nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo," Free Radical Biology and Medicine, vol. 66, pp. 24-35, 2014.
20. L. M. Aleksunes and J. E. Manautou, "Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease," Toxicologic Pathology, vol. 35, no. 4, pp. 459-473, 2007.
21. D. Siegel, D. L. Gustafson, D. L. Dehn et al., "NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger," Molecular Pharmacology, vol. 65, no. 5, pp. 1238-1247, 2004.
22. I. N. Zelko, T. J. Mariani, R. J. Folz, "Superoxide dismutase multigene family: a comparison of theCuZn-SOD(SOD1),Mn-SOD (SOD2), EC-SOD (SOD3) gene structures, evolution, expression," Free Radical Biology and Medicine, vol. 33, no. 3, pp. 337-349, 2002.
23. A. Perkins, K. J. Nelson, D. Parsonage, L. B. Poole, P. A. Karplus, "Peroxiredoxins: guardians against oxidative stress and modulators of peroxide signaling," Trends in Biochemical Sciences, vol. 40, no. 8, pp. 435-445, 2015.
24. R. Brigelius-Flohé and M.Maiorino, "Glutathione peroxidases," Biochimica et Biophysica Acta-General Subjects, vol. 1830, no. 5, pp. 3289-3303, 2013.
25. A. B. Fisher, C. Dodia, Y. Manevich, J.-W. Chen, S. I. Feinstein, "Phospholipid hydroperoxides are substrates for nonselenium glutathione peroxidase," The Journal of Biological Chemistry, vol. 274, no. 30, pp. 21326-21334, 1999.
26. H. Imai and Y. Nakagawa, "Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells," Free Radical Biology and Medicine, vol. 34, no. 2, pp. 145-169, 2003.
27. Y.Manevich, T. Sweitzer, J. H. Pak, S. I. Feinstein,V.Muzykantov, A. B. Fisher, "1-Cys peroxiredoxin overexpression protects cells against phospholipid peroxidation-mediated membrane damage," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 18, pp. 11599-11604, 2002.
28. A. M. K. Choi and J. Alam, "Heme oxygenase-1: function, regulation, implication of a novel stress-inducible protein in oxidant-induced lung injury," American Journal of Respiratory Cell and Molecular Biology, vol. 15, no. 1, pp. 9-19, 1996.
29. E.-M. Hanschmann, J. R. Godoy, C. Berndt, C. Hudemann, C. H. Lillig, "Thioredoxins, glutaredoxins, peroxiredoxinsmolecular mechanisms and health significance: From cofactors to antioxidants to redox signaling," Antioxidants and Redox Signaling, vol. 19, no. 13, pp. 1539-1605, 2013.
30. A. G. Cox, C. C. Winterbourn, M. B. Hampton, "Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling," Biochemical Journal, vol. 425, no. 2, pp. 313-325, 2010.
31. K. Aoyama and T.Nakaki, "Glutathione in cellular redox homeostasis: association with the Excitatory Amino Acid Carrier 1 (EAAC1)," Molecules, vol. 20, no. 5, pp. 8742-8758, 2015.
32. C. L.Hawkins and M. J.Davies, "Detection and characterisation of radicals in biological materials using EPR methodology," Biochimica et Biophysica Acta-General Subjects, vol. 1840, no. 2, pp. 708-721, 2014.
33. B. Kalyanaraman, V. Darley-Usmar, K. J. A. Davies et al., "Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations," Free Radical Biology and Medicine, vol. 52, no. 1, pp. 1-6, 2012.
34. J. Zielonka, A. Sikora, M. Hardy, J. Joseph, B. P. Dranka, B. Kalyanaraman, "Boronate probes as diagnostic tools for real time monitoring of peroxynitrite and hydroperoxides," Chemical Research in Toxicology, vol. 25, no. 9, pp. 1793-1799, 2012.
35. K. A. Lukyanov and V. V. Belousov, "Genetically encoded fluorescent redox sensors," Biochimica et Biophysica Acta-General Subjects, vol. 1840, no. 2, pp. 745-756, 2014.
36. D. S. Bilan and V. V. Belousov, "HyPer family probes: state of the art," Antioxidants & Redox Signaling, vol. 24, no. 13, pp. 731-751, 2016.
37. B.Morgan, K. Van Laer, T. N. Owusu et al., "Real-time monitoring of basal H2O2 levels with peroxiredoxin-based probes," Nature Chemical Biology, vol. 12, no. 6, pp. 437-443, 2016.
38. I. Emerit, "Clastogenic factors as potential biomarkers of increased superoxide production," Biomark Insights, vol. 2, pp. 429-438, 2007.
39. M. N. Alam, N. J. Bristi, M. Rafiquzzaman, "Review on in vivo and in vitro methods evaluation of antioxidant activity," Saudi Pharmaceutical Journal, vol. 21, no. 2, pp. 143-152, 2013.
40. O. Erel, "A new automated colorimetric method for measuring total oxidant status," Clinical Biochemistry, vol. 38, no. 12, pp. 1103-11111, 2005.
41. M. R.Higgs, P. Chouteau, H. Lerat, "'Liver let die': oxidative DNA damage and hepatotropic viruses," Journal of General Virology, vol. 95, no. 5, pp. 991-1004, 2014.
42. A.V. Ivanov, B. Bartosch,O.A. Smirnova,M. G. Isaguliants, S.N. Kochetkov, "HCVand oxidative stress in the liver," Viruses, vol. 5, no. 2, pp. 439-469, 2013.
43. V. Williams, S. Brichler, E. Khan et al., "Large hepatitis delta antigen activates STAT-3 and NF-B via oxidative stress," Journal of Viral Hepatitis, vol. 19, no. 10, pp. 744-753, 2012.
44. Q. Ma, L. E. Cavallin, H. J. Leung, C. Chiozzini, P. J. Goldschmidt-Clermont, E. A. Mesri, "A role for virally induced reactive oxygen species in Kaposi's sarcoma herpesvirus tumorigenesis," Antioxidants and Redox Signaling, vol. 18, no. 1, pp. 80-90, 2013.
45. S. A. Kamranvar and M. G. Masucci, "The Epstein-Barr virus nuclear antigen-1 promotes telomere dysfunction via induction of oxidative stress," Leukemia, vol. 25, no. 6, pp. 1017-1025, 2011.
46. R. P. Garofalo, D. Kolli, A. Casola, "Respiratory syncytial virus infection: mechanisms of redox control and novel therapeutic opportunities," Antioxidants & Redox Signaling, vol. 18, no. 2, pp. 186-217, 2013.
47. M. Strengert, R. Jennings, S. Davanture, P. Hayes, G. Gabriel, U. G. Knaus, "Mucosal reactive oxygen species are required for antiviral response: role of duox in influenza a virus infection," Antioxidants & Redox Signaling, vol. 20, no. 17, pp. 2695-2709, 2014.
48. E. O. Freed and M. A. Martin, "HIVs and their replication," in Fields Virology, D. M. Knipe and P. M. Howley, Eds., pp. 2107-2185, Lippincott, Williams & Wilkins, Philadelphia, Pa, USA, 2007.
49. D. R. Kuritzkes and B. D. Walker, "HIV-1 pathigenesis, clinical manifestations and treatment," in Fields Virology, D. M. Knipe and P. M. Howley, Eds., pp. 2187-2214, Williams & Wilkins, Philadelphia, Pa, USA, 2007.
50. http://www.fda.gov/ForPatients/Illness/HIVAIDS/Treatment/ucm118915.htm.
51. H.Samji,A.Cescon, R. S.Hogg et al., "Closing thegap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada," PLoS ONE, vol. 8, no. 12, Article ID e81355, 2013.
52. P. Volberding, Sande's HIV/AIDS Medicine. Global Care, 2nd edition, 2012.
53. C. Elbim, S. Pillet, M. H. Prevost et al., "Redox and activation status of monocytes from human immunodeficiency virusinfected patients: relationship with viral load," Journal of Virology, vol. 73, no. 6, pp. 4561-4566, 1999.
54. A. Sönnerborg, G. Carlin, B. Akerlund, C. Jarstrand, "Increased production of malondialdehyde in patients with HIV infection," Scandinavian Journal of Infectious Diseases, vol. 20, no. 3, pp. 287-290, 1988.
55. J.-P. Revillard, C. M. A. Vincent, A. E. Favier, M.-J. Richard, M. Zittoun,M. D. Kazatchkine, "Lipid peroxidation in human immunodeficiency virus infection," Journal of Acquired Immune Deficiency Syndromes, vol. 5, no. 6, pp. 637-638, 1992.
56. A.Wanchu, S. V. Rana, S. Pallikkuth, R. K. Sachdeva, "Short communication:Oxidative stress inHIV-infected individuals: a cross-sectional study," AIDS Research and Human Retroviruses, vol. 25, no. 12, pp. 1307-1311, 2009.
57. J. P. Allard, E. Aghdassi, J. Chau, I. Salit, S. Walmsley, "Oxidative stress and plasma antioxidant micronutrients in humans with HIV infection,"The American Journal of Clinical Nutrition, vol. 67, no. 1, pp. 143-147, 1998.
58. L. M. Watanabe, F. Barbosa Júnior, A. A. Jordaõ, A. M. Navarro, "Influence of HIV infection and the use of antiretroviral therapy on selenium and selenomethionine concentrations and antioxidant protection," Nutrition, vol. 32, no. 11-12, pp. 1238-1242, 2016.
59. G. Teto, G. D. Kanmogne, J. N. Torimiro et al., "Lipid peroxidation and total cholesterol in HAART-Näve Patients infected with circulating recombinant forms of human immunodeficiency virus type-1 in cameroon," PLoS ONE, vol. 8, no. 6, Article ID e65126, 2013.
60. M.Kalinowska, D. A. Bazdar,M.M. Lederman,N. Funderburg, S. F. Sieg, "Decreased IL-7 responsiveness is related to oxidative stress in hiv disease," PLoS ONE, vol. 8, no. 3, Article ID e58764, 2013.
61. O. Awodele, S. O. Olayemi, J. A. Nwite, T. A. Adeyemo, "Investigation of the levels of oxidative stress parameters in HIV and HIV-TB co-infected patients," Journal of Infection in Developing Countries, vol. 6, no. 1, pp. 79-85, 2012.
62. P. Aukrust, L. Luna, T. Ueland et al., "Impaired base excision repair and accumulation of oxidative base lesions in CD4+ T cells of HIV-infected patients," Blood, vol. 105, no. 12, pp. 4730-4735, 2005.
63. L. Gil, G. Martnez, I. González et al., "Contribution to characterization of oxidative stress in HIV/AIDS patients," Pharmacological Research, vol. 47, no. 3, pp. 217-224, 2003.
64. R. C. Strange, M. A. Spiteri, S. Ramachandran, A. A. Fryer, "Glutathione-S-transferase family of enzymes," Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, vol. 482, no. 1-2, pp. 21-26, 2001.
65. M. Parsons, A. Campa, S. Lai et al., "Effect of GSTM1-polymorphism on disease progression and oxidative stress in HIV infection: modulation by HIV/HCV co-infection and alcohol consumption," Journal of AIDS and Clinical Research, vol. 4, article 237, 2013.
66. F. J. T. Staal, M. Roederer, D. M. Israelski et al., "Intracellular glutathione levels in T cell subsets decrease in HIV-infected individuals," AIDS Research and Human Retroviruses, vol. 8, no. 2, pp. 305-311, 1992.
67. F. J. T. Staal, S. W. Ela, M. Roederer, M. T. Anderson, L. A. Herzenberg, L. A.Herzenberg, "Glutathione deficiency and human immunodeficiency virus infection," The Lancet, vol. 339, no. 8798, pp. 909-912, 1992.
68. P. Aukrust, A. M. Svardal, F. Muller et al., "Increased levels of oxidized glutathione in CD4+ lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type 1 infection," Blood, vol. 86, no. 1, pp. 258-267, 1995.
69. N. J. Haughey, R. G. Cutler, A. Tamara et al., "Perturbation of sphingolipid metabolism and ceramide production in HIVdementia," Annals of Neurology, vol. 55,no. 2, pp. 257-267, 2004.
70. K. Banki, E. Hutter, N. J. Gonchoroff, A. Perl, "Molecular ordering in HIV-induced apoptosis. Oxidative stress, activation of caspases, cell survival are regulated by transaldolase,"The Journal of Biological Chemistry, vol. 273, no. 19, pp. 11944-11953, 1998.
71. S. L. Deshmane, R. Mukerjee, S. Fan et al., "Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1 expression," The Journal of Biological Chemistry, vol. 284, no. 17, pp. 11364-11373, 2009.
72. E. J. Jareño, F. Bosch-Morell, R. Fernández-Delgado, J. Donat, F. J. Romero, "Serum malondialdehyde inHIV-seropositive children negatively correlates with CD4+ lymphocytes count," BioFactors, vol. 8, no. 1-2, pp. 129-132, 1998.
73. A. Elias, B.Nelson,D.Oputiri,O.-B. P.Geoffrey, "Antiretroviral toxicity and oxidative stress," American Journal of Pharmacology and Toxicology, vol. 8, no. 4, pp. 187-196, 2013.
74. X. Huang, H. Liang, X. Fan, L. Zhu, T. Shen, "Liver damage in patients with HCV/HIV coinfection is linked to HIV-related oxidative stress," OxidativeMedicine and Cellular Longevity, vol. 2016, Article ID 8142431, 11 pages, 2016.
75. M. K. Baum, S. Sales, D. T. Jayaweera et al., "Coinfection with hepatitis C virus, oxidative stress and antioxidant status inHIVpositive drug users in Miami," HIV Medicine, vol. 12, no. 2, pp. 78-86, 2011.
76. Y. Zhang, M. Wang, H. Li et al., "Accumulation of nuclear and mitochondrial DNA damage in the frontal cortex cells of patients with HIV-associated neurocognitive disorders," Brain Research, vol. 1458, pp. 1-11, 2012.
77. E. R. Kline, D. J. Kleinhenz, B. Liang et al., "Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are reversed by glutathione restoration," American Journal of Physiology-Heart and Circulatory Physiology, vol. 294, no. 6, pp. H2792-H2804, 2008.
78. B. A. Jacob, K. M. Porter, S. C. Elms, P.-Y. Cheng, D. P. Jones, R. L. Sutliff, "HIV-1-induced pulmonary oxidative and nitrosative stress: exacerbated response to endotoxin administration in HIV-1 transgenic mouse model," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 291, no. 4, pp. L811-L819, 2006.
79. A. Shah, S. Kumar, S. D. Simon, D. P. Singh, A. Kumar, "HIV gp120-and methamphetamine-mediated oxidative stress induces astrocyte apoptosis via cytochrome P450 2E1," Cell Death and Disease, vol. 4, no. 10, article e850, 2013.
80. L. Guo, Y. Xing, R. Pan et al., "Curcumin protects microglia and primary rat cortical neurons againstHIV-1 gp120-mediated inflammation and apoptosis," PLoSONE, vol. 8, no. 8,Article ID e70565, 2013.
81. P. T. Ronaldson and R. Bendayan, "HIV-1 viral envelope glycoprotein gp120 produces oxidative stress and regulates the functional expression of multidrug resistance protein-1 (Mrp1) in glial cells," Journal ofNeurochemistry, vol. 106, no. 3,pp. 1298-1313, 2008.
82. V. A. Shatrov, F. Ratter, A. Gruber, W. Dröge, V. Lehmann, "HIV type 1 glycoprotein 120 amplifies tumor necrosis factorinduced NF-B activation in Jurkat cells," AIDS Research and Human Retroviruses, vol. 12, no. 13, pp. 1209-1216, 1996.
83. T. O. Price, N. Ercal, R. Nakaoke, W. A. Banks, "HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells," Brain Research, vol. 1045, no. 1-2, pp. 57-63, 2005.
84. A. Banerjee, X. Zhang, K. R. Manda, W. A. Banks, N. Ercal, "HIV proteins (gp120 and Tat) and methamphetamine in oxidative stress-induced damage in the brain: potential role of the thiol antioxidant N-acetylcysteine amide," Free Radical Biology and Medicine, vol. 48, no. 10, pp. 1388-1398, 2010.
85. J. Pandhare, S. Dash, B. Jones, F.Villalta, C.Dash, "A novel role of proline oxidase in HIV-1 envelope glycoprotein-induced neuronal autophagy," The Journal of Biological Chemistry, vol. 290, no. 42, pp. 25439-25451, 2015.
86. Y. Gu, R. F. Wu, Y. C. Xu, S. C. Flores, L. S. Terada, "HIV Tat activates c-Jun amino-terminal kinase through an oxidantdependentmechanism," Virology, vol. 286, no. 1,pp. 62-71, 2001.
87. M. Toborek, Y. W. Lee, H. Pu et al., "HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium," Journal of Neurochemistry, vol. 84, no. 1, pp. 169-179, 2003.
88. R. Mastrantonio, M. Cervelli, S. Pietropaoli et al., "HIV-Tat induces the Nrf2/ARE pathway through NMDA receptorelicited spermine oxidase activation in human neuroblastoma cells," PLoS ONE, vol. 11, no. 2, Article ID e0149802, 2016.
89. F. Vilhardt, O. Plastre,M. Sawada et al., "The HIV-1 Nef protein and phagocyte NADPH oxidase activation," The Journal of Biological Chemistry, vol. 277, no. 44, pp. 42136-42143, 2002.
90. E. Olivetta,D. Pietraforte, I. Schiavoni,M.Minetti,M. Federico,M. Sanchez, "HIV-1 Nef regulates the release of superoxide anions from human macrophages," Biochemical Journal, vol. 390, no. 2, pp. 591-602, 2005.
91. S. Salmen, M. Colmenares, D. L. Peterson, E. Reyes, J. D. Rosales, L. Berrueta, "HIV-1 Nef associates with p22-phox, a component of the NADPH oxidase protein complex," Cellular Immunology, vol. 263, no. 2, pp. 166-171, 2010.
92. C. Arunagiri, I. Macreadie, D. Hewish, A. Azad, "A Cterminal domain of HIV-1 accessory protein Vpr is involved in penetration, mitochondrial dysfunction and apoptosis of human CD4+ lymphocytes," Apoptosis, vol. 2, no. 1, pp. 69-76, 1997.
93. Z. Gazdag, T. Stromájer-Rácz, J. Belagyi et al., "Regulation of unbalanced redox homeostasis induced by the expression of wild-type HIV-1 viral protein R (NL4-3Vpr) in fission yeast," Acta Biologica Hungarica, vol. 66, no. 3, pp. 326-338, 2015.
94. M. Isaguliants, O. Smirnova, A. V. Ivanov et al., "Oxidative stress induced by HIV-1 reverse transcriptase modulates the enzyme's performance in gene immunization," Human Vaccines and Immunotherapeutics, vol. 9, no. 10, pp. 2111-2119, 2013.
95. I. O. Foga, A. Nath, B. B. Hasinoff, J. D. Geiger, "Antioxidants and dipyridamole inhibit HIV-1 gp120-induced free radical-based oxidative damage to human monocytoid cells," Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 16, no. 4, pp. 223-229, 1997.
96. D. Pietraforte, E. Tritarelli, U. Testa, M. Minetti, "gp120 HIV envelope glycoprotein increases the production of nitric oxide in human monocyte-derived macrophages," Journal of Leukocyte Biology, vol. 55, no. 2, pp. 175-182, 1994.
97. C. Capone,M. Cervelli, E. Angelucci et al., "A role for spermine oxidase as a mediator of reactive oxygen species production in HIV-Tat-induced neuronal toxicity," Free Radical Biology and Medicine, vol. 63, pp. 99-107, 2013.
98. S. W. Perry, J. P. Norman, A. Litzburg, D. Zhang, S. Dewhurst, H. A. Gelbard, "HIV-1 transactivator of transcription protein induces mitochondrial hyperpolarization and synaptic stress leading to apoptosis," The Journal of Immunology, vol. 174, no. 7, pp. 4333-4344, 2005.
99. R.-F. Wu, Z.Ma, Z. Liu, L. S. Terada, "Nox4-derived H2O2 mediates endoplasmic reticulum signaling through local ras activation," Molecular and Cellular Biology, vol. 30, no. 14, pp. 3553-3568, 2010.
100. I. Helmcke, S. Heumüller, R. Tikkanen, K. Schröder, R. P. Brandes, "Identification of structural elements in Nox1 and Nox4 controlling localization and activity," Antioxidants and Redox Signaling, vol. 11, no. 6, pp. 1279-1287, 2009.
101. T. Ramming, H. G. Hansen, K. Nagata, L. Ellgaard, C. Appenzeller-Herzog, "GPx8 peroxidase prevents leakage of H2O2 from the endoplasmic reticulum," Free Radical Biology and Medicine, vol. 70, pp. 106-116, 2014.
102. M. Malinouski, Y. Zhou, V. V. Belousov, D. L. Hatfield, V. N. Gladyshev, "Hydrogen peroxide probes directed to different cellular compartments," PLoS ONE, vol. 6, no. 1, Article ID e14564, 2011.
103. J. Birk, T. Ramming, A. Odermatt, C. Appenzeller-Herzog, "Green fluorescent protein-based monitoring of endoplasmic reticulum redox poise," Frontiers in Genetics, vol. 4, article 108, 2013.
104. F. R. Laurindo, L. A. Pescatore, C. Fernandes Dde, "Protein disulfide isomerase in redox cell signaling and homeostasis," Free Radical Biology & Medicine, vol. 52, no. 9, pp. 1954-1969, 2012.
105. G. Li, M.Mongillo, K.-T. Chin et al., "Role of ERO1-mediated stimulation of inositol 1,4,5-triphosphate receptor activity in endoplasmic reticulum stress-induced apoptosis," Journal of Cell Biology, vol. 186, no. 6, pp. 783-792, 2009.
106. T. J. Tavender and N. J. Bulleid, "Peroxiredoxin IV protects cells from oxidative stress by removing H2O2 produced during disulphide formation," The Journal of Cell Science, vol. 123, no. 15, pp. 2672-2679, 2010.
107. L. Wang, L. Zhang, Y. Niu, R. Sitia, C.-C. Wang, "Glutathione peroxidase 7 utilizes hydrogen peroxide generated by Ero1 to promote oxidative protein folding," Antioxidants and Redox Signaling, vol. 20, no. 4, pp. 545-556, 2014.
108. T. Stromájer-Rácz, Z. Gazdag, J. Belágyi, C. Vágvölgyi, R. Y. Zhao, M. Pesti, "Oxidative stress induced byHIV-1 F34IVpr in Schizosaccharomyces pombe is one of itsmultiple functions," Experimental andMolecular Pathology, vol. 88, no. 1, pp. 38-44, 2010.
109. I. G. Macreadie, D. R. Thorburn, D. M. Kirby, L. A. Castelli, N. L. de Rozario, A. A. Azad, "HIV-1 protein Vpr causes gross mitochondrial dysfunction in the yeast Saccharomyces cerevisiae," FEBS Letters, vol. 410, no. 2-3, pp. 145-149, 1997.
110. A. P. Halestrap and C. Brenner, "The adenine nucleotide translocase: a central component of the mitochondrial permeability transition pore and key player in cell death," Current Medicinal Chemistry, vol. 10, no. 16, pp. 1507-1525, 2003.
111. M. Okuda, K. Li, M. R. Beard et al., "Mitochondrial injury, oxidative stress, antioxidant gene expression are induced by hepatitis C virus core protein," Gastroenterology, vol. 122, no. 2, pp. 366-375, 2002.
112. S. L. McClain, A. J. Clippinger, R. Lizzano, M. J. Bouchard, "Hepatitis B virus replication is associated with an HBxdependent mitochondrion-regulated increase in cytosolic calcium levels," Journal of Virology, vol. 81, no. 21, pp. 12061-12065, 2007.
113. H. J. Kim, C.-H. Kim, J.-H. Ryu et al., "Reactive oxygen species induce antiviral innate immune response through IFN-regulation in human nasal epithelial cells," American Journal of Respiratory Cell andMolecular Biology, vol. 49, no. 5, pp. 855-865, 2013.
114. A.V. Ivanov,O.A. Smirnova, I. Y. Petrushanko et al., "HCVcore protein uses multiple mechanisms to induce oxidative stress in human hepatoma Huh7 cells," Viruses, vol. 7, no. 6, pp. 2745-2770, 2015.
115. O. A. Smirnova, O. N. Ivanova, B. Bartosch et al., "Hepatitis C virus NS5A protein triggers oxidative stress by inducing NADPH oxidases 1 and 4 and cytochrome P450 2E1," Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 8341937, 10 pages, 2016.
116. D. Amatore, R. Sgarbanti, K. Aquilano et al., "Influenza virus replication in lung epithelial cells depends on redox-sensitive pathways activated by NOX4-derived ROS," CellularMicrobiology, vol. 17, no. 1, pp. 131-145, 2015.
117. S. Selemidis, H. J. Seow, B. R. S. Broughton et al., "Nox1 oxidase suppresses influenza a virus-induced lung inflammation and oxidative stress," PLoS ONE, vol. 8, no. 4, Article ID e60792, 2013.
118. E. E. To, B. R. S. Broughton, K. S. Hendricks, R. Vlahos, S. Selemidis, "Influenza A virus and TLR7 activation potentiate NOX2 oxidase-dependent ROS production in macrophages," Free Radical Research, vol. 48, no. 8, pp. 940-947, 2014.
119. H. E. Boudreau, S. U. Emerson, A. Korzeniowska, M. A. Jendrysik, T. L. Leto, "Hepatitis C virus (HCV) proteins induce NADPH oxidase 4 expression in a transforming growth factor-dependent manner: a newcontributor toHCVinduced oxidative stress," Journal of Virology, vol. 83, no. 24, pp. 12934-12946, 2009.
120. N. S. R. DeMochel, S. Seronello, S.H.Wang et al., "Hepatocyte NAD(P)Hoxidases as an endogenous source of reactive oxygen species during hepatitis C virus infection," Hepatology, vol. 52, no. 1, pp. 47-59, 2010.
121. K. Fink,A.Duval,A.Martel, A. Soucy-Faulkner,N. Grandvaux, "Dual role of NOX2 in respiratory syncytial virus-and sendai virus-induced activation of NF-B in airway epithelial cells," The Journal of Immunology, vol. 180, no. 10, pp. 6911-6922, 2008.
122. M. Y. Gwarzo and S. A. Muhammad, "Extracellular superoxide dismutase activity and plasma malondialdehyde in human immunodeficiency virus subjects of kano state as surrogate markers of CD4 status," International Journal of Biomedical Science, vol. 6, no. 4, pp. 294-300, 2010.
123. T. Samikkannu, D. Ranjith, K. V. K. Rao et al., "HIV-1 gp120 and morphine induced oxidative stress: role in cell cycle regulation," Frontiers in Microbiology, vol. 6, article 614, 2015.
124. J. C. Marecki, A. Cota-Gomez,G.M.Vaitaitis et al., "HIV-1 Tat regulates the SOD2 basal promoter by altering Sp1/Sp3 binding activity," Free Radical Biology and Medicine, vol. 37, no. 6, pp. 869-880, 2004.
125. S. C. Flores, J.C.Marecki,K. P.Harper, S. K. Bose, S.K.Nelson, J. M. McCord, "Tat protein of human immunodeficiency virus type 1 represses expression of manganese superoxide dismutase in HeLa cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 16, pp. 7632-7636, 1993.
126. M.-J. Richard, P. Guiraud, C. Didier, M. Seve, S. C. Flores, A. Favier, "Human immunodeficiency virus type 1 Tat protein impairs selenoglutathione peroxidase expression and activity by a mechanism independent of cellular selenium uptake: consequences on cellular resistance to UV-A radiation," Archives of Biochemistry and Biophysics, vol. 386, no. 2, pp. 213-220, 2001.
127. V. Visalli, C. Muscoli, I. Sacco et al., "N-acetylcysteine prevents HIV gp 120-related damage of human cultured astrocytes: correlation with glutamine synthase dysfunction," BMC Neuroscience, vol. 8, article 106, 2007.
128. N. Monroy, L. Herrero, L. Carrasco, M. E. González, "Influence of glutathione availability on cell damage induced by human immunodeficiency virus type 1 viral protein R," Virus Research, vol. 213, pp. 116-123, 2016.
129. K. Mehdi and M. J. Penninckx, "An important role for glutathione and-glutamyltranspeptidase in the supply of growth requirements during nitrogen starvation of the yeast Saccharomyces cerevisiae," Microbiology, vol. 143, no. 6, pp. 1885-1889, 1997.
130. A. J. Gill, C. E. Kovacsics, P. J. Vance, R. G. Collman, D. L. Kolson, "Induction of heme oxygenase-1 deficiency and associated glutamate-mediated neurotoxicity is a highly conserved HIV phenotype of chronic macrophage infection that is resistant to antiretroviral therapy," Journal of Virology, vol. 89, no. 20, pp. 10656-10667, 2015.
131. A. J. Gill, C. E. Kovacsics, S. A. Cross et al., "Heme oxygenase-1 deficiency accompanies neuropathogenesis of HIV-associated neurocognitive disorders,"The Journal of Clinical Investigation, vol. 124, no. 10, pp. 4459-4472, 2014.
132. D.Burdette,M. Olivarez,G.Waris, "Activationof transcription factor Nrf2 by hepatitis C virus induces the cell-survival pathway," Journal of General Virology, vol. 91, no. 3, pp. 681-690, 2010.
133. A.V. Ivanov, O. A. Smirnova, O. N. Ivanova, O. V. Masalova, S. N.Kochetkov,M. G. Isaguliants, "Hepatitis C virus proteins activate NRF2/ARE pathway by distinct ROS-dependent and independentmechanisms inHUH7 cells," PLoS ONE, vol. 6, no. 9, Article ID e24957, 2011.
134. Y. Jiang, H. Bao, Y. Ge et al., "Therapeutic targeting of GSK3 enhances the Nrf2 antioxidant response and confers hepatic cytoprotection in hepatitis C," Gut, vol. 64, no. 1, pp. 168-179, 2015.
135. M. Carvajal-Yepes, K. Himmelsbach, S. Schaedler et al., "Hepatitis C virus impairs the induction of cytoprotectiveNrf2 target genes by delocalization of small maf proteins," The Journal of Biological Chemistry, vol. 286, no. 11, pp. 8941-8951, 2011.
136. V. Pialoux, R. Mounier, A. D. Brown, C. D. Steinback, J. M. Rawling, M. J. Poulin, "Relationship between oxidative stress andHIF-1 mRNA during sustained hypoxia in humans," Free Radical Biology and Medicine, vol. 46, no. 2, pp. 321-326, 2009.
137. A. A. Qutub and A. S. Popel, "Reactive oxygen species regulate hypoxia-inducible factor 1 differentially in cancer and ischemia," Molecular and Cellular Biology, vol. 28, no. 16, pp. 5106-5119, 2008.
138. S.-I. Kurata, "Sensitization of the HIV-1-LTR upon long term low dose oxidative stress," The Journal of Biological Chemistry, vol. 271, no. 36, pp. 21798-21802, 1996.
139. F. J. T. Staal, M. Roederer, P. A. Raju et al., "Antioxidants inhibit stimulation of HIV transcription," AIDS Research and Human Retroviruses, vol. 9, no. 4, pp. 299-306, 1993.
140. Q. Dong, S. Kelkar, Y. Xiao, S. Joshi-Barve, C. J.McClain, S. S. Barve, "Ethanol enhances TNF-inducible NFB activation and HIV-1-LTR transcription in CD4+ Jurkat T lymphocytes," Journal of Laboratory and Clinical Medicine, vol. 136, no. 5, pp. 333-343, 2000.
141. E. J. Duh,W. J.Maury, T.M. Folks, A. S. Fauci,A.B.Rabson, "Tumor necrosis factor activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-B sites in the long terminal repeat," Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 15, pp. 5974-5978, 1989.
142. F. J. T. Staal, M. Roederer, L. A. Herzenberg, L. A. Herzenberg, "Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus," Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 24, pp. 9943-9947, 1990.
143. L. A. Pereira, K. Bentley, A. Peeters, M. J. Churchill, N. J. Deacon, "A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter," Nucleic Acids Research, vol. 28, no. 3, pp. 663-668, 2000.
144. A. Bhaskar, M. Munshi, S. Z. Khan et al., "Measuring glutathione redox potential of HIV-1-infected macrophages," The Journal of Biological Chemistry, vol. 290, no. 2, pp. 1020-1038, 2015.
145. C. S. Palmer, C. L. Cherry, I. Sada-Ovalle, A. Singh, S.M. Crowe, "Glucose metabolism in T cells and monocytes: new perspectives inHIV pathogenesis," EBioMedicine, vol. 6, pp. 31-41, 2016.
146. A. T. Palamara, C.-F. Perno, S. Aquaro,M. C. Buè, L. Dini, E. Garaci, "Glutathione inhibits HIV replication by acting at late stages of the virus life cycle," AIDS Research and Human Retroviruses, vol. 12, no. 16, pp. 1537-1541, 1996.
147. X. Lan, K. Cheng, N. Chandel et al., "High glucose enhances HIV entry into T cells through upregulation of CXCR4," Journal of Leukocyte Biology, vol. 94, no. 4, pp. 769-777, 2013.
148. E.Garaci,A. T. Palamara, M. R. Ciriolo et al., "Intracellular GSH content and HIV replication in humanmacrophages," Journal of Leukocyte Biology, vol. 62, no. 1, pp. 54-59, 1997.
149. R. Sgarbanti, L. Nencioni,D. Amatore et al., "Redox regulation of the influenza hemagglutinin maturation process: a new cellmediated strategy for anti-influenza therapy," Antioxidants and Redox Signaling, vol. 15, no. 3, pp. 593-606, 2011.
150. M. A. Chetram and C. V. Hinton, "ROS-mediated regulation of CXCR4 in cancer," Frontiers in Biology, vol. 8, no. 3,pp. 273-278, 2013.
151. S. Andrisse, R. M. Koehler, J. E. Chen et al., "Role of GLUT1 in regulation of reactive oxygen species," Redox Biology, vol. 2, no. 1, pp. 764-771, 2014.
152. L. R. Sorbara, F. Maldarelli, G. Chamoun et al., "Human immunodeficiency virus type 1 infection of H9 cells induces increased glucose transporter expression," Journal of Virology, vol. 70, no. 10, pp. 7275-7279, 1996.
153. C. A. Kovitz and S. Morgello, "Cerebral glucose transporter expression inHIVinfection," Acta Neuropathologica, vol. 94,no. 2, pp. 140-145, 1997.
154. B. Bartosch, "Hepatitis C virus and its complex interplay with hepatic glucose and lipid metabolism," Journal of Hepatology, vol. 50, no. 5, pp. 845-847, 2009.
155. P. Lévy and B. Bartosch, "Metabolic reprogramming: a hallmark of viral oncogenesis," Oncogene, vol. 35, no. 32, pp. 4155-4164, 2016.
156. C.-H. Wu, C.-F. Wu, H.-W. Huang, Y.-C. Jao, G.-C. Yen, "Naturally occurring flavonoids attenuate high glucose-induced expression of proinflammatory cytokines in human monocytic THP-1 cells,"Molecular Nutrition and Food Research, vol. 53, no. 8, pp. 984-995, 2009.
157. K. Yao, J.-B. Ge, A.-J. Sun et al., "Effects and mechanism of hyperglycemia on development and maturation and immune function of humanmonocyte derived dendritic cells," Zhonghua Xin Xue Guan Bing Za Zhi, vol. 34, no. 1, pp. 60-64, 2006.
158. P. A. Sandstrom, J. Murray, T. M. Folks, A. M. Diamond, "Antioxidant defenses influence HIV-1 replication and associated cytopathic effects," Free Radical Biology and Medicine, vol. 24, no. 9, pp. 1485-1491, 1998.
159. M. Kaul, G. A. Garden, S. A. Lipton, "Pathways to neuronal injury and apoptosis in HIV-associated dementia," Nature, vol. 410, no. 6831, pp. 988-994, 2001.
160. K. J. Kallianpur, M.Gerschenson, B. I.Mitchell et al., "Oxidative mitochondrial DNA damage in peripheral blood mononuclear cells is associated with reduced volumes of hippocampus and subcortical gray matter in chronically HIV-infected patients," Mitochondrion, vol. 28, pp. 8-15, 2016.
161. O. Galicia, M. Sanchez-Alavez, M. Mendez Diaz, L. Navarro, O. Prospero-Garcia, "HIV glycoprotein 120: possible etiological agent of AIDS-associated dementia," Revista de Investigaci ón Cĺnica, vol. 54, no. 5, pp. 437-452, 2002.
162. D. E. Brenneman, S. K. McCune, R. F. Mervis, J. M. Hill, "gp120 as an etiologic agent for NeuroAIDS: neurotoxicity and model systems," Advances inNeuroimmunology, vol. 4, no. 3,pp. 157-165, 1994.
163. J.-P. Louboutin, L. Agrawal, B. A. S. Reyes, E. J. Van Bockstaele, D. S. Strayer, "HIV-1 gp120-induced injury to the blood-brain barrier: role of metalloproteinases 2 and 9 and relationship to oxidative stress," Journal of Neuropathology and Experimental Neurology, vol. 69, no. 8, pp. 801-816, 2010.
164. R. Xu, X. Feng, X. Xie, J. Zhang, D. Wu, L. Xu, "HIV-1 Tat protein increases the permeability of brain endothelial cells by both inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9," Brain Research, vol. 1436, pp. 13-19, 2012.
165. M. Toborek, Y. W. Lee, G. Flora et al., "Mechanisms of the blood-brain barrier disruption in HIV-1 infection," Cellular and Molecular Neurobiology, vol. 25, no. 1, pp. 181-199, 2005.
166. A. Ferrucci,M. R. Nonnemacher, E. A. Cohen, B.Wigdahl, "Extracellular human immunodeficiency virus type 1 viral protein R causes reductions in astrocytic ATP and glutathione levels compromising the antioxidant reservoir," Virus Research, vol. 167, no. 2, pp. 358-369, 2012.
167. A. Ferrucci, M. R. Nonnemacher, B. Wigdahl, "Extracellular HIV-1 viral protein R affects astrocytic glyceraldehyde 3-phosphate dehydrogenase activity and neuronal survival," Journal of NeuroVirology, vol. 19, no. 3, pp. 239-253, 2013.
168. S. Hoshino, M. Konishi, M. Mori et al., "HIV-1 Vpr induces TLR4/MyD88-mediated IL-6 production and reactivates viral production from latency," Journal of Leukocyte Biology, vol. 87, no. 6, pp. 1133-1143, 2010.
169. L. Chen, J. Liu,C.Xu, J. Keblesh,W. Zang,H. Xiong, "HIV-1gp120 induces neuronal apoptosis through enhancement of 4-aminopyridine-senstive outward K+ currents," PLoS ONE, vol. 6, no. 10, Article ID e25994, 2011.
170. H. Tomitori, T. Usui, N. Saeki et al., "Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke," Stroke, vol. 36, no. 12, pp. 2609-2613, 2005.
171. P. L. Wood, M. A. Khan, J. R.Moskal, K. G. Todd, V. A.M. I. Tanay, G. Baker, "Aldehyde load in ischemia-reperfusion brain injury: neuroprotection by neutralization of reactive aldehydes with phenelzine," Brain Research, vol. 1122, no. 1, pp. 184-190, 2006.
172. S.M. Dever, R. Xu, S.Fitting,P.E.Knapp,K. F.Hauser, "Differential expression and HIV-1 regulation of-opioid receptor splice variants across human central nervous system cell types," Journal of NeuroVirology, vol. 18, no. 3, pp. 181-190, 2012.
173. I. Sudano, L. E. Spieker, G. Noll, R. Corti, R. Weber, T. F. Lüscher, "Cardiovascular disease in HIV infection," American Heart Journal, vol. 151, no. 6, pp. 1147-1155, 2006.
174. L. E. Spieker, B. Karadag, C. Binggeli, R. Corti, "Rapid progression of atherosclerotic coronary artery disease in patients with human immunodeficiency virus infection," Heart and Vessels, vol. 20, no. 4, pp. 171-174, 2005.
175. D. Bonnet, Y. Aggoun, I. Szezepanski, N. Bellal, S. Blanche, "Arterial stiffness and endothelial dysfunction in HIV-infected children," AIDS, vol. 18, no. 7, pp. 1037-1041, 2004.
176. P. Paton, A. Tabib, R. Loire, R. Tete, "Coronary artery lesions and humanimmunodeficiency virus infection," Research in Virology, vol. 144, no. 3, pp. 225-231, 1993.
177. V. V. Joshi, B. Pawel, E. Connor et al., "Arteriopathy in children with acquired immune deficiency syndrome," Fetal and Pediatric Pathology, vol. 7, no. 3, pp. 261-275, 1987.
178. J. Cadranel, D. Garfield, A. Lavolé, M. Wislez, B. Milleron, C. Mayaud, "Lung cancer in HIV infected patients: facts, questions and challenges," Thorax, vol. 61, no. 11, pp. 1000-1008, 2006.
179. J.M. Beck, M. J. Rosen,H.H. Peavy, "Pulmonary complications of HIV infection. Report of the fourth NHLBI workshop," American Journal of Respiratory and Critical CareMedicine, vol. 164, no. 11, pp. 2120-2126, 2001.
180. X. Fan, B. S. Staitieh, J. S. Jensen et al., "Activating the Nrf2-mediated antioxidant response element restores barrier function in the alveolar epithelium of HIV-1 transgenic rats," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 305, no. 3, pp. L267-L277, 2013.
181. S. Brundu, L. Palma, G. G. Picceri et al., "Glutathione depletion is linked with th2 polarization in mice with a retrovirusinduced immunodeficiency syndrome, murine AIDS: role of proglutathione molecules as immunotherapeutics," Journal of Virology, vol. 90, no. 16, pp. 7118-7130, 2016.
182. N.W. S.Davies, G.Guillemin, B. J. Brew, "Tryptophan, neurodegeneration and HIV-associated neurocognitive disorder," International Journal of Tryptophan Research, vol. 3, no. 1, pp. 121-140, 2010.
183. G. Zilberman-Schapira, N. Zmora, S. Itav, S. Bashiardes, H. Elinav, E. Elinav, "The gut microbiome in human immunodeficiency virus infection," BMCMedicine, vol. 14, no. 1, article 83, 2016.
184. C.M. Forrest, G.M.Mackay,N. Stoy et al., "Tryptophan loading induces oxidative stress," Free Radical Research, vol. 38, no. 11, pp. 1167-1171, 2004.
185. B. Baban, A. M. Hansen, P. R. Chandler et al., "A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation," International Immunology, vol. 17, no. 7, pp. 909-919, 2005.
186. K. Schröcksnadel, B. Wirleitner, C. Winkler, D. Fuchs, "Monitoring tryptophan metabolism in chronic immune activation," Clinica Chimica Acta, vol. 364, no. 1-2, pp. 82-90, 2006.
187. S. E. Bosinger, Q. Li, S. N. Gordon et al., "Global genomic analysis reveals rapid control of a robust innate response in SIVinfected sooty mangabeys,"The Journal of Clinical Investigation, vol. 119, no. 12, pp. 3556-3572, 2009.
188. M. Hoshi, K. Saito, A. Hara et al., "The absence of IDO upregulates type I IFN production, resulting in suppression of viral replication in the retrovirus-infected mouse," The Journal of Immunology, vol. 185, no. 6, pp. 3305-3312, 2010.
189. M. A. O'Connor and W. R. Green, "The role of indoleamine 2,3-dioxygenase in LP-BPM5murine retroviral disease progression," Virology Journal, vol. 10, article 154, 2013.
190. A. Boasso, J.-P. Herbeuval, A. W. Hardy et al., "HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells," Blood, vol. 109, no. 8, pp. 3351-3359, 2007.
191. H. Soliman, M. Mediavilla-Varela, S. Antonia, "Indoleamine 2,3-dioxygenase: is it an immune suppressor" Cancer Journal, vol. 16, no. 4, pp. 354-359, 2010.
192. A. L. Mellor and D. H. Munn, "IDO expression by dendritic cells: tolerance and tryptophan catabolism," Nature Reviews Immunology, vol. 4, no. 10, pp. 762-774, 2004.
193. A. Boasso, M. Vaccari, A. Hryniewicz et al., "Regulatory Tcell markers, indoleamine 2,3-dioxygenase, virus levels in spleen and gut during progressive simian immunodeficiency virus infection," Journal of Virology, vol. 81, no. 21, pp. 11593-11603, 2007.
194. D. Favre, J. Mold, P. W. Hunt et al., "Tryptophan catabolism by indoleamine 2, 3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease," Science Translational Medicine, vol. 2, no. 32, Article ID32-36, 2010.
195. A. Boasso, M. Vaccari, J. Nilsson et al., "Do regulatory T-cells play a role in AIDS pathogenesis" AIDS Reviews, vol. 8, no. 3, pp. 141-147, 2006.
196. A. Boasso and G. M. Shearer, "How does indoleamine 2,3-dioxygenase contribute to HIV-mediated immune dysregulation," Current Drug Metabolism, vol. 8, no. 3, pp. 217-223, 2007.
197. L. K. Nzowa, R. B. Teponno, L. A. Tapondjou et al., "Two new tryptophan derivatives from the seed kernels of Entada rheedei: effects on cell viability and HIV infectivity," Fitoterapia, vol. 87, pp. 37-42, 2013.
198. W.Malorni,R. Rivabene, B.M. Lucia et al., "The role of oxidative imbalance in progression to AIDS: effect of the thiol supplierNacetylcysteine," AIDS Research and Human Retroviruses, vol. 14, no. 17, pp. 1589-1596, 1998.
199. P. Aukrust, A.M. Svardal, F.Müller,B. Lunden, R. K. Berge, S. S. Frøland, "Decreased levels of total and reduced glutathione in CD4+ lymphocytes in common variable immunodeficiency are associated with activation of the tumor necrosis factor system: possible immunopathogenic role of oxidative stress," Blood, vol. 86, no. 4, pp. 1383-1391, 1995.
200. L.Uzasci, A.Nath, R. Cotter, "Oxidative stress and theHIVinfected brain proteome," Journal of Neuroimmune Pharmacology, vol. 8, no. 5, pp. 1167-1180, 2013.
201. J. V. Esplugues, "NO as a signalling molecule in the nervous system," British Journal of Pharmacology, vol. 135, no. 5, pp. 1079-1095, 2002.
202. E. Polazzi, G. Levi, L. Minghetti, "Human immunodeficiency virus type 1 Tat protein stimulates inducible nitric oxide synthase expression and nitric oxide production in microglial cultures," Journal of Neuropathology and Experimental Neurology, vol. 58, no. 8, pp. 825-831, 1999.
203. X. Liu, M. Jana, S. Dasgupta et al., "Human immunodeficiency virus type 1 (HIV-1) tat induces nitric-oxide synthase in human astroglia,"The Journal of Biological Chemistry, vol. 277, no. 42, pp. 39312-39319, 2002.
204. D. C. Adamson, K. L. Kopnisky, T. M. Dawson, V. L. Dawson, "Mechanisms and structural determinants of HIV-1 coat protein, gp41-induced neurotoxicity," The Journal of Neuroscience, vol. 19, no. 1, pp. 64-71, 1999.
205. Q.-R. Yu, Z.-P. Zhang, H. Zhang et al., "Inducible nitric oxide synthase is involved in the oxidation stress induced by HIV-1 gp120 in human retina pigment epithelial cells," ChineseMedical Journal, vol. 121, no. 24, pp. 2578-2583, 2008.
206. G. Mangino, M. Famiglietti, C. Capone et al., "HIV-1 myristoylated nef treatment ofmurine microglial cells activates inducible nitric oxide synthase, NO2 production and neurotoxic activity," PLoS ONE, vol. 10, no. 6, Article IDe0130189, 2015.
207. M. Garcá, A. M. Del Llano, E. Cruz-Colón, S. Saavedra, J. A. Lavergne, J. A. Lavergne, "Characteristics of nitric oxideinduced apoptosis and its target cells in mitogen-stimulated peripheral blood mononuclear cells from HIV+ subjects," Immunological Investigations, vol. 30, no. 4, pp. 267-287, 2001.
208. S. Banerjee, L. Liao, R. Russo et al., "Isobaric tagging-based quantification by mass spectrometry of differentially regulated proteins in synaptosomes of HIV/gp120 transgenic mice: implications for HIV-associated neurodegeneration," Experimental Neurology, vol. 236, no. 2, pp. 298-306, 2012.
209. J. Steiner, N. Haughey, W. Li et al., "Oxidative stress and therapeutic approaches in HIV dementia," Antioxidants and Redox Signaling, vol. 8, no. 11-12, pp. 2089-2100, 2006.
210. K. Hori, P. R. Burd, K. Furuke, J. Kutza, K. A. Weih, K. A. Clouse, "Human immunodeficiency virus-1-infected macrophages induce inducible nitric oxide synthase and nitric oxide (NO) production in astrocytes: astrocytic NO as a possible mediator of neural damage in acquired immunodeficiency syndrome," Blood, vol. 93, no. 6, pp. 1843-1850, 1999.
211. S. Hu, H. Ali, W. S. Sheng, L. C. Ehrlich, P. K. Peterson, C. C. Chao, "Gp-41-mediated astrocyte inducible nitric oxide synthase mRNA expression: involvement of interleukin-1beta production by microglia,"The Journal of Neuroscience, vol. 19, no. 15, pp. 6468-6474, 1999.
212. D. C. Adamson, J. C. McArthur, T.M.Dawson, V. L.Dawson, "Rate and severity of HIV-associated dementia (HAD): correlations with Gp41 and iNOS," Molecular Medicine, vol. 5, no. 2, pp. 98-109, 1999.
213. W. Li, T. M. Malpica-Llanos, R. Gundry et al., "Nitrosative stress with HIV dementia causes decreased L-prostaglandin D synthase activity," Neurology, vol. 70, no. 19, part 2, pp. 1753-1762, 2008.
214. L. Uzasci, M. A. Bianchet, R. J. Cotter, A. Nath, "Identification of nitrated immunoglobulin variable regions in the HIV-infected human brain: implications in HIV infection and immune response," Journal of Proteome Research, vol. 13, no. 3, pp. 1614-1623, 2014.
215. J. González-Nicolás, S. Resino, J. L. Jiménez, S. Alvarez, M. Fresno, M. A. Muñoz-Fernández, "Tumor necrosis factoralpha and nitric oxide in vertically HIV-1-infected children: implications for pathogenesis," European Cytokine Network, vol. 12, no. 3, pp. 437-444, 2001.
216. M. D. Mossalayi, P.-A. Becherel, P. Debré, "Critical role of nitric oxide during the apoptosis of peripheral blood leukocytes from patients with aids," Molecular Medicine, vol. 5, no. 12, pp. 812-819, 1999.
217. J. L. Jiménez, J. González-Nicolás, S. Alvarez, M. Fresno, M. A. Muñoz-Fernández, "Regulation of human immunodeficiency virus type 1 replication in human T lymphocytes by nitric oxide," Journal of Virology, vol. 75, no. 10, pp. 4655-4663, 2001.
218. J. B. Mannick, J. S. Stamler, E. Teng et al., "Nitric oxide modulates HIV-1 replication," Journal of Acquired Immune Deficiency Syndromes, vol. 22, no. 1, pp. 1-9, 1999.
219. T. Persichini, M. Colasanti, G. M. Lauro, P. Ascenzi, "Cysteine nitrosylation inactivates the HIV-1 protease," Biochemical and Biophysical Research Communications, vol. 250, no. 3, pp. 575-576, 1998.
220. P. K. Sehajpal, A. Basu, J. S. Ogiste, H. M. Lander, "Reversible S-nitrosation and inhibition of HIV-1 protease," Biochemistry, vol. 38, no. 40, pp. 13407-13413, 1999.
221. E. Cairoli, D. Scott-Algara, O. Pritsch, G. Dighiero, A. Cayota, "HIV-1 induced decrease of nitric oxide production and inducible nitric oxide synthase expression during in vivo and in vitro infection," Clinical Immunology, vol. 127, no. 1, pp. 26-33, 2008.
222. A.D. Badley, A. Sainski, F.Wightman, S. R. Lewin, "Altering cell death pathways as an approach to cure HIV infection," Cell Death and Disease, vol. 4, article e718, 2013.
223. X. Wang, H. Chai, P. H. Lin, Q. Yao, C. Chen, "Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells," The American Journal of Pathology, vol. 174, no. 3, pp. 771-781, 2009.
224. S.Nagiah, A. Phulukdaree, A. Chuturgoon, "Mitochondrial and oxidative stress response inHepG2 cells following acute and prolonged exposure to antiretroviral drugs," Journal of Cellular Biochemistry, vol. 116, no. 9, pp. 1939-1946, 2015.
225. K. R. Manda, A. Banerjee,W. A. Banks, N. Ercal, "Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells," Free Radical Biology and Medicine, vol. 50, no. 7, pp. 801-810, 2011.
226. D. Mondal, L. Pradhan, M. Ali, K. C. Agrawal, "HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants," Cardiovascular Toxicology, vol. 4, no. 3, pp. 287-302, 2004.
227. B. E.Hurwitz,N.G. Klimas, M. M. Llabre et al., "HIV,metabolic syndrome X, inflammation, oxidative stress, coronary heart disease risk: role of protease inhibitor exposure," Cardiovascular Toxicology, vol. 4, no. 3, pp. 303-315, 2004.
228. S. Chandra, D. Mondal, K. C. Agrawal, "HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone," Experimental Biology and Medicine, vol. 234, no. 4, pp. 442-453, 2009.
229. M. Weiß, B.Kost, I. Renner-Müller, E.Wolf, I.Mylonas, A. Brüning, "Efavirenz causes oxidative stress, endoplasmic reticulum stress, autophagy in endothelial cells," Cardiovascular Toxicology, vol. 16, no. 1, pp. 90-99, 2016.
230. M.Masiá, S. Padilla, E. Bernal et al., "Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients," Clinical Therapeutics, vol. 29, no. 7, pp. 1448-1455, 2007.
231. A.Mandas, E. L. Iorio, M. G.Congiu et al., "Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy," Journal of Biomedicine and Biotechnology, vol. 2009, Article ID 749575, 7 pages, 2009.
232. L. Gil, A. Tarinas, D. Hernández et al., "Altered oxidative stress indexes related to disease progression marker in human immunodeficiency virus infected patients with antiretroviral therapy," Biomedicine & Aging Pathology, vol. 1, no. 1, pp. 8-15, 2011.
233. J. L.Ngondi, J.Oben,D.M. Forkah,L.H.Etame,D.Mbanya, "The effect of different combination therapies on oxidative stress markers in HIV infected patients in Cameroon," AIDS Research andTherapy, vol. 3, no. 1, article 19, 2006.
234. C. K. Sen, "Cellular thiols and redox-regulated signal transduction," Current Topics in Cellular Regulation, vol. 36, pp. 1-30, 2001.
235. W. O. Opii, R. Sultana, H. M. Abdul, M. A. Ansari, A. Nath, D. A. Butterfield, "Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)-2,3-dideoxycytidine (ddC): relevance to HIV-dementia," Experimental Neurology, vol. 204, no. 1, pp. 29-38, 2007.
236. B. J. Day and W. Lewis, "Oxidative stress in NRTI-induced toxicity: evidence from clinical experience and experiments in vitro and in vivo," Cardiovascular Toxicology, vol. 4, no. 3, pp. 207-216, 2004.
237. K. Sevastianova, J. Sutinen, J. Westerbacka, M. Ristola, H. Yki-Järvinen, "Arterial stiffness inHIV-infected patients receiving highly active antiretroviral therapy," Antiviral Therapy, vol. 10, no. 8, pp. 925-935, 2005.
238. M. G. A. van Vonderen, Y. M. Smulders, C. D. A. Stehouwer et al., "Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, lipodystrophy," Journal of Acquired Immune Deficiency Syndromes, vol. 50, no. 2, pp. 153-161, 2009.
239. K. Becker, S. Gromer, R. H. Schirmer, S. Müller, "Thioredoxin reductase as a pathophysiological factor and drug target," European Journal of Biochemistry, vol. 267, no. 20, pp. 6118-6125, 2000.
240. B. Chirullo, R. Sgarbanti, D. Limongi et al., "A candidate anti-HIV reservoir compound, auranofin, exerts a selective 'antimemory' effect by exploiting the baseline oxidative status of lymphocytes," Cell Death and Disease, vol. 4, article e944, 2013.
241. M. G. Lewis, S. DaFonseca, N. Chomont et al., "Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension," AIDS, vol. 25, no. 11, pp. 1347-1356, 2011.
242. I. L. Shytaj, B. Chirullo, W. Wagner et al., "Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS," Retrovirology, vol. 10, article 71, 2013.
243. I. A. M. Vint, B. M. Chain, J. C. Foreman, "The interaction of auranofin and buthionine sulfoximine blocks activation of human peripheral T lymphocytes," Cellular Immunology, vol. 152, no. 1, pp. 152-161, 1993.
244. I. L. Shytaj, G. Nickel, E. Arts et al., "Two-year follow-up of macaques developing intermittent control of the human immunodeficiency virus homolog simian immunodeficiency virus SIVmac251 in the chronic phase of infection," Journal of Virology, vol. 89, no. 15, pp. 7521-7535, 2015.